SOM-1311 (SOM-0011) is under development for the treatment of phenylketonuria. The drug candidate is a repurposed drug and is pharmacological chaperone of phenylalanine hydroxylase. The drug candidate ...
make in the product. It can be attractive to just do what the rest of the industry is doing. For instance, one study of 458 pharmaceutical and biotechnology license agreements found a 7% average ...
which acknowledges “extraordinary scientific innovations that improve the human condition”, has awarded its Best Biotechnology Product 2022 accolade to Regeneron Pharmaceuticals, Inc.’ ...
A specialty therapeutics company developing therapeutics for the treatment of cancer and infectious diseases. Ascletis is an R&D driven biotech with two commercial products and listed on the Hong Kong ...
The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered in London, the ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
“These products are currently being manufactured in Europe, manufacturing these in India opens further collaboration opportunities with other global pharma companies to optimize their manufacturing ...